GlassScriptPhysician profile
Catherine A Walker
NPI 1730702499
$10,716.34
in general payments reported to CMS, 2019-2025
36 companies · $2,734 in 2025
The $2,734 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,430 · 2022: $1,889 · 2023: $2,070 · 2024: $2,593 · 2025: $2,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,201 · Education: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,200.96 |
| Education | $196.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,013.32 | 2021-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,094.25 | 2021-2025 | Trelegy Ellipta, Nucala |
| Regeneron Healthcare Solutions, INC. | $907.21 | 2021-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $747.56 | 2021-2025 | Ofev, Jascayd, Stiolto Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $558.96 | 2021-2025 | Glassia, Cuvitru, Gammagard |
| Mylan Specialty L.P. | $522.58 | 2021-2024 | Yupelri |
| Mallinckrodt Hospital Products INC. | $453.91 | 2021-2025 | Acthar |
| United Therapeutics Corporation | $423.64 | 2021-2025 | Tyvaso, Tyvaso |
| Grifols USA, LLC | $409.26 | 2021-2025 | Prolastin-C Liquid, Xembify |
| Ani Pharmaceuticals, INC. | $335.76 | 2024 | Purified Cortrophin Gel |
| Shionogi INC | $306.28 | 2022-2025 | Fetroja |
| Amgen INC. | $279.66 | 2021-2025 | Tezspire |
| Merck Sharp & Dohme LLC | $268.63 | 2021-2025 | Zerbaxa, Dificid, Recarbrio |
| Actelion Pharmaceuticals US, INC. | $268.55 | 2023-2025 | Opsumit, Uptravi, Opsynvi |
| Genzyme Corporation | $249.06 | 2021-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $243.62 | 2025 | Ohtuvayre |
| Insmed, INC. | $219.38 | 2022-2025 | Arikayce, Brinsupri |
| Genentech USA, INC. | $191.96 | 2021-2025 | Xolair |
| Inogen, INC. | $171.06 | 2022-2025 | Inogen At Home Stationary Concentrator, Inogen One G5 Oxygen Concentrator - Bluetooth, Inogen One G3 Oxygen Concentrator |
| Viatris Specialty LLC | $166.09 | 2025 | Yupelri |
| Electromed, INC. | $150.56 | 2022-2025 | Smartvest |
| Philips North America LLC | $146.99 | 2022-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Baxter Healthcare | $109.15 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Bayer Healthcare Pharmaceuticals INC. | $89.12 | 2023 | |
| Alexion Pharmaceuticals, INC. | $72.37 | 2022 | |
| Astellas Pharma US INC | $56.89 | 2021 | |
| Medtronic, INC. | $49.45 | 2024-2025 | Illumisite |
| Mayne Pharma Commercial LLC | $48.17 | 2021-2022 | |
| Sandoz INC. | $31.06 | 2023 | Treprostinil |
| Paratek Pharmaceuticals, INC. | $24.88 | 2022 | |
| Ucb, INC. | $21.94 | 2024 | Briviact |
| Novartis Pharmaceuticals Corporation | $19.20 | 2023 | Leqvio |
| Tactile Systems Technology INC | $17.77 | 2024 | Entre Plus, Flexitouch Plus |
| Liquidia Technologies, INC. | $17.44 | 2025 | Yutrepia |
| Covis Pharma Gmbh | $16.26 | 2022 | |
| Vapotherm INC | $14.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.